reported survival of CNS xenografts for up to 6 weeks in two AD mouse models utilizing mAbs targeting LFA‐1, CD40 and CTLA‐4, representing an improvement over traditional immunosuppressant drugs. This evidence concerns the gene CTLA4 and Alzheimer disease.